Caligan Partners as of Sept. 30, 2024
Portfolio Holdings for Caligan Partners
Caligan Partners holds 12 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 25.7 | $81M | 8.1M | 10.00 | |
| Verona Pharma Sponsored Ads (VRNA) | 13.1 | $41M | 1.4M | 28.77 | |
| Exelixis (EXEL) | 12.6 | $40M | 1.5M | 25.95 | |
| Evolus (EOLS) | 11.3 | $36M | 2.2M | 16.20 | |
| Anika Therapeutics (ANIK) | 11.2 | $35M | 1.4M | 24.70 | |
| Agios Pharmaceuticals (AGIO) | 8.2 | $26M | 580k | 44.43 | |
| BioCryst Pharmaceuticals (BCRX) | 6.2 | $20M | 2.6M | 7.60 | |
| Y Mabs Therapeutics | 5.0 | $16M | 1.2M | 13.15 | |
| Mineralys Therapeutics (MLYS) | 3.8 | $12M | 981k | 12.11 | |
| I Mab Sponsored Ads (IMAB) | 1.4 | $4.3M | 3.5M | 1.24 | |
| Enanta Pharmaceuticals (ENTA) | 1.1 | $3.3M | 323k | 10.36 | |
| Outlook Therapeutics (OTLK) | 0.5 | $1.7M | 319k | 5.34 |
